Shape the Future of Precision-Driven Cancer Care
Where Three Events Come Together as One:
Establish South Korea as a Hub of Innovation to Create Best & First Class ADCs, Bispecifics, T-Cell Engagers, and Protein Degraders that Deliver More Targeted, Efficacious & Safer Therapies for Patients
보다 표적화되고, 효능이 뛰어나며, 안전한 치료제를 환자에게 제공하는 최고·최초 수준의 ADC, 이중특이 항체, T세포 엔게이저 및 단백질 분해제를 개발하기 위한 혁신 허브로서 대한민국을 확립하세요
South Korea is fast becoming the epicenter of targeted therapeutics innovation, particularly on ADCs, bispecifics, T-Cell Engagers and TPDs converge.
To meet the growing demand for safer, more effective drugs with broader therapeutic windows that can improve on standard of care treatments and meet an unmet medical need, the World Targeted Therapeutics Summit South Korea brings together three of the hottest modalities under one roof to create unparalleled opportunities for idea exchange, collaboration, and networking.
Taking place as three co-located events with the flagship 5th World ADC South Korea Summit, and the brand new World Bispecific & T-Cell Engager Summit South Korea and the World TPD & Induced Proximity Summit South Korea, this is your opportunity to gain comprehensive coverage of the fastest-growing R&D areas in Korea.
With an audience ranging from C-level execs and VP/Directors, join over 400 leading experts to drive innovation, differentiate your pipeline and accelerate precision-driven cancer care.
Event Highlights
행사 하이라이트
Official Partners
공식 파트너
Attending Companies Include
참석 기업에는 다음이 포함됩니다
Explore Related Events
관련 행사 둘러보기
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.